TactiCath® Prospective Effectiveness Pilot Study

Inclusion Criteria: * Patient is at least 18 years of age but not over 75 years of age * Patient has at least one episode of sustained (\>30s) paroxysmal atrial fibrillation documented by 12-lead ECG, holter monitor, transtelephonic event monitor, telemetry strip, or Pacemaker respectively implantable cardioverter defibrillator (ICD) within 12 months prior to enrolment * Patient has symptomatic paroxysmal atrial fibrillation (PAF) refractory or intolerant to at least one Class I-IV anti-arrhythmic drug * Patient is willing and capable of complying with the study protocol requirements, including the specified follow-up scheme * Patient provides written informed consent prior to enrolment in the study Exclusion Criteria: * Not adhering to inclusion criteria * Active systemic infection * Recent (within 3 months) cardiac events including myocardial infarction, acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery * Reversible causes of Arrhythmia including thyroid disorders, acute alcohol intoxication, recent (less than 3 months) major surgical procedures * Patient has a left atrial diameter \> 5.0 cm * Patient has persistent or long-standing persistent atrial fibrillation (AF) * Left ventricular ejection fraction \< 35% * New York Heart Association (NYHA) class III or IV * Previous left atrial heart ablation procedure, either surgical or catheter ablation * Patient has an intracardiac mural thrombus or has had a ventriculotomy or atriotomy * Patient has moderate or severe structural heart disease as demonstrated by transthoracic or trans-esophageal echocardiogram of all four chambers of the heart (ventricular dysfunction or valve disease) * Tricuspid or mitral valve replacement or repair * If female of childbearing potential - pregnant or breastfeeding * Patient has a bleeding diathesis or suspected pro-coagulant state * Patient has contraindication to long-term antithromboembolic therapy (e. g. acetylsalicylic acid, heparin, warfarin) * Presence of condition that precludes appropriate vascular access * Heart disease in which corrective surgery is anticipated within 6 months * Renal failure requiring dialysis * Patient has a known sensitivity to contrast media (if needed during the procedure) that cannot adequately be controlled with pre-medication (or totally excluded) * Patient has other anatomic or co-morbid conditions that, in the Investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results * Patient is currently participating in another clinical trial * Patient is unlikely to survive over one year